Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 106

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 106
---

is based, in part, on our know-how and trade secrets, a competitor’s independent discovery of our trade secrets or other unauthorized
use or disclosure would impair our competitive position and may have a material adverse effect on our business.

In addition, these agreements
typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating
to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that
we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration and any joint R&D
programs may require us to share trade secrets under the terms of our R&D or similar agreements. Despite our efforts to protect our
trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent
development or publication of information by any of our third-party collaborators. A competitor’s discovery of our trade secrets
would impair our competitive position and have an adverse impact on our business.

We may not have sufficient patent lifespan to effectively protect our products and business.

All of our patents are in
early stages. Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years
after its earliest U.S. non-provisional filing date. Given the amount of time required for the development, testing and regulatory
review of new product candidates, patents protecting such candidates might expire before or shortly after the resulting products are
commercialized. As a result, our patents may not provide us with sufficient rights to exclude others from commercializing products similar
or identical to ours. We expect to seek extensions of patent terms for our issued patents, where available. This includes in the United States
under the Hatch-Waxman Act, which permits a patent term extension of up to five years beyond the original expiration date of the
patent as compensation for regulatory delays. However, such a patent term extension cannot lengthen the remaining term of a patent beyond
a total of 14 years from the product’s approval date. Only one patent applicable to an approved drug is eligible for the extension
and the application for the extension must be submitted prior to the expiration of the patent. During the period of patent term extension,
the claims of a patent are not enforceable for their full scope but are instead limited to the scope of the approved product. In addition,
the applicable authorities, including the FDA in the United States, and any comparable foreign regulatory authorities, may not agree